Search Results - "Rheumatology (Oxford, England)"

Refine Results
  1. 1

    The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies by Rees, Frances, Doherty, Michael, Grainge, Matthew J, Lanyon, Peter, Zhang, Weiya

    Published in Rheumatology (Oxford, England) (01-11-2017)
    “…The aim was to review the worldwide incidence and prevalence of SLE and variation with age, sex, ethnicity and time. A systematic search of MEDLINE and EMBASE…”
    Get full text
    Journal Article
  2. 2

    A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis by Bechman, Katie, Subesinghe, Sujith, Norton, Sam, Atzeni, Fabiola, Galli, Massimo, Cope, Andrew P, Winthrop, Kevin L, Galloway, James B

    Published in Rheumatology (Oxford, England) (01-10-2019)
    “…Abstract Objectives To evaluate the risk of serious infection (SI) and herpes zoster (HZ) in rheumatoid arthritis patients receiving JAK inhibitors. Methods We…”
    Get full text
    Journal Article
  3. 3

    Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series by Furer, Victoria, Zisman, Devy, Kibari, Adi, Rimar, Doron, Paran, Yael, Elkayam, Ori

    Published in Rheumatology (Oxford, England) (09-10-2021)
    “…Objectives As global vaccination campaigns against COVID-19 disease commence, vaccine safety needs to be closely assessed. The safety profile of mRNA-based…”
    Get full text
    Journal Article
  4. 4

    JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis by Fragoulis, George E, McInnes, Iain B, Siebert, Stefan

    Published in Rheumatology (Oxford, England) (01-02-2019)
    “…Abstract Janus kinase (JAK)/signal transducers and activators of transcription (STATs) are a group of molecules associated with one of the major pathways…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Clinical significance of Janus Kinase inhibitor selectivity by Choy, Ernest H

    Published in Rheumatology (Oxford, England) (01-06-2019)
    “…Cytokines are key drivers of inflammation in RA, and anti-cytokine therapy has improved the outcome of RA. Janus Kinases (JAK) are intracellular tyrosine…”
    Get full text
    Journal Article
  7. 7

    Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis by Kurasawa, Kazuhiro, Arai, Satoko, Namiki, Yumeko, Tanaka, Ayae, Takamura, Yuta, Owada, Takayoshi, Arima, Masafumi, Maezawa, Reika

    Published in Rheumatology (Oxford, England) (01-12-2018)
    “…Abstract Objective We aimed to determine the outcome of combination therapy with tofacitinib (TOF) in a case series of refractory rapidly progressive…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10
  11. 11

    Osteoarthritis: the genesis of pain by Fu, Kai, Robbins, Sarah R, McDougall, Jason J

    Published in Rheumatology (Oxford, England) (01-05-2018)
    “…Abstract OA is a painful joint disease that predominantly affects the elderly. Pain is the primary symptom of OA, and it can present as either intermittent or…”
    Get full text
    Journal Article
  12. 12

    Osteosarcopenia: where osteoporosis and sarcopenia collide by Clynes, Michael A, Gregson, Celia L, Bruyère, Olivier, Cooper, Cyrus, Dennison, Elaine M

    Published in Rheumatology (Oxford, England) (01-02-2021)
    “…Abstract The coexistence of osteoporosis and sarcopenia has been recently considered in some groups as a syndrome termed ‘osteosarcopenia’. Osteoporosis…”
    Get full text
    Journal Article Web Resource
  13. 13

    The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease by Dejaco, Christian, Duftner, Christina, Buttgereit, Frank, Matteson, Eric L, Dasgupta, Bhaskar

    Published in Rheumatology (Oxford, England) (01-04-2017)
    “…GCA and PMR are conditions of older persons that frequently overlap. The traditional concept of GCA has focused on cranial symptoms such as headache and visual…”
    Get full text
    Journal Article
  14. 14

    Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors by Weinmann, Sophia C, Pisetsky, David S

    Published in Rheumatology (Oxford, England) (01-12-2019)
    “…Abstract Immune checkpoint inhibitors are novel biologic agents to treat cancer by inhibiting the regulatory interactions that limit T cell cytotoxicity to…”
    Get full text
    Journal Article
  15. 15
  16. 16

    Lupus nephritis: clinical presentations and outcomes in the 21st century by Gasparotto, Michela, Gatto, Mariele, Binda, Valentina, Doria, Andrea, Moroni, Gabriella

    Published in Rheumatology (Oxford, England) (05-12-2020)
    “…Abstract Lupus nephritis (LN) is a frequent and severe manifestation of SLE. Along the decades, the epidemiology of LN and its clinical presentation have been…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19

    What drives osteoarthritis?-synovial versus subchondral bone pathology by Hügle, Thomas, Geurts, Jeroen

    Published in Rheumatology (Oxford, England) (01-09-2017)
    “…Subchondral bone and the synovium play an important role in the initiation and progression of OA. MRI often permits an early detection of synovial hypertrophy…”
    Get full text
    Journal Article
  20. 20

    Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial by Sircar, Geetabali, Goswami, Rudra Prosad, Sircar, Dipankar, Ghosh, Alakendu, Ghosh, Parasar

    Published in Rheumatology (Oxford, England) (01-12-2018)
    “…Abstract Objectives SSc is characterized by fibrotic changes in the skin and lung, and the mainstay of treatment has been CYC. B cell involvement suggests that…”
    Get full text
    Journal Article